Monday, 20 February 2017
Last updated 2 days ago
Apr 22 2014 | 2:03pm ET
For its latest activist effort, Pershing Square Capital Management has already enlisted a buyer.
The New York-based hedge fund and Valeant Pharmaceuticals have joined forces in a hostile bid for Allergan Inc., the pharmaceutical company that makes Botox. Since striking its agreement with Valeant, Pershing Square has bought up some 9.7% of Allergan’s shares.
The deal, for cash and Valeant stock, is worth in excess of $45 billion.
Valeant has been seeking a deal for Allergan for a year, to no avail. The company said the merger would “create an unrivaled platform for growth and value creation in healthcare.”